AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida.
| Revenue (Most Recent Fiscal Year) | $0.17M |
| Net Income (Most Recent Fiscal Year) | $-17.32M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 38.62 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -10416.44% |
| Net Margin (Trailing 12 Months) | -10416.44% |
| Return on Equity (Trailing 12 Months) | -1586.23% |
| Return on Assets (Trailing 12 Months) | -137.76% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.26 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.05 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.05 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.31 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.24 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 72.29M |
| Free Float | 65.49M |
| Market Capitalization | $5.64M |
| Average Volume (Last 20 Days) | 0.11M |
| Beta (Past 60 Months) | 1.03 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.41% |
| Percentage Held By Institutions (Latest 13F Reports) | 12.02% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |